New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
07:13 EDTATRS, ACTAntares Pharma reports Q4 EPS (4c), consensus (5c)
Antares Pharma (ATRS) reports Q4 revenue $4.75M, consensus $6.15M. The company said "Product revenue decreased in Q4 to $0.9M. The decrease in product revenues in Q4 was primarily due to a decrease in sales of oxybutynin gel 3% product to Actavis (ACT), as Actavis assumed all manufacturing of Gelnique 3% in 1Q13, as contracted.
News For ATRS;ACT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ATRS;ACT

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use